LONDON, Sept 14 (Reuters) - Johnson & Johnson’s (JNJ.N: Quote, Profile, Research) Cypher drug-coated stent is less likely to cause late stent thrombosis or heart attacks than Boston Scientific’s (BSX.N: Quote, Profile, Research) rival product Taxus or bare-metal stents, Swiss researchers said on Friday. The findings from a large pooled, or meta- analysis of clinical trials may help physicians decide how best to use the controversial drug-covered scaffolds that prop open clogged coronary arteries, the team said.
